The MESEPAD project “MEchanisms of SEx-specific vulnerability of Parvalbumin interneurons in early Alzheimer’s Disease”, officially launched in January 2025, is one of the 10 projects selected for funding by the European Joint Programme Neurodegenerative Disease Research (more) in 2024. The project has received a total funding of €800,000 euros and will run for 3 years (2025-2027), with approximately €170,000 allocated to our institute.
Laure Verret (CRCA-CBI) is participating in this project which aims to understand gender differences in Alzheimer’s Disease (AD); and is part of a European consortium coordinated by Prof. Carlos Saura from the Universitat Autònoma de Barcelona (Spain). The consortium also includes Dr. Alberto Lleó from the Hospital de la Santa Creu i Sant Pau (Barcelona, Spain) and Dr. Ronald E. Van Kesteren from Vrije Universiteit Amsterdam (Netherlands), with the collaboration of Prof. Philip De Jager from Columbia University (USA).
AD is the leading cause of dementia in the aging population, disproportionately affecting women compared to men (2:1). However, the cellular, molecular and pathogenic mechanisms underlying these sex differences in AD risk and progression remain unknown. Understanding these mechanisms is critical for developing personalized diagnostic and therapeutic strategies. The MESEPAD partnership aims to identify key molecular mechanisms underlying early structural and functional changes associated with sex-specific AD vulnerability.
Latest news
